Will one of the more educated posters fill me in on what we can interpret from the 50% clinical remission and 50% partial response designations? Since this is a small trial, can this be considered statistically significant, or are they very positive results which will still need evaluation in a larger scale phase 2 study?
That said; I interpret the results as fantastic news and I think that the trial will ultimately validate/justify some BP partnership funding to move the Brilacidin GI platform forward.